Another Epidemiological Study Finds Glucosamine Associated with Reduced Mortality
Glucosamine (credit: AndresJS) |
Sometimes I lurk on various life extension message boards
and am perplexed that many (most?) people do not list glucosamine in their
pro-longevity 'stack' even though its use is associated with reduction in all-cause mortality. Glucosamine is cheap and relatively well-tolerated. While
association does not mean causation, the relationship has been found in
several large epidemiological studies and holds up when controlling for various demographic factors; similar associations have not been found for other
supplements - not even fish oil or vitamin D. There are some plausible
mechanisms, which I don't have time to really get into, unfortunately. In brief, glucosamine inhibits glucose metabolism (see Ristow interview linked below) - which could have direct effects and also effects via the gut microbiome, increases hyaluronic acid production, and may have other effects relating to O-GlcNAcylation (that's what I'm most interested in).
News article on the most recent study: https://www.bicycling.com/health-nutrition/a34854230/glucosamine-supplements-may-reduce-risk-of-early-death-study/
The research article: https://www.jabfm.org/content/jabfp/33/6/842.full.pdf
An interview with longevity researcher Michael Ristow on glucosamine: http://geroscience.com/glucosamine-the-new-metformin-interview-with-dr-michael-ristow-part-ii/
Dose makes the poison, don't OD: https://www.sciencedaily.com/releases/2010/10/101027111349.htm
Glucosamine is typically derived from shellfish and may not be appropriate for people with shellfish allergies. I had to stop taking it when I started having MCAS / 'histamine intolerance' symptoms as it seemed to make my symptoms worse (creatine did the same).
Would it be good or bad for Parkinson's disease? Can't even speculate - especially since I need to read more on the O-GlcNAcylation thing. The Mischley et al. (2017) study did not list glucosamine among the supplements: https://www.hindawi.com/journals/omcl/2017/6405278/tab3/
There is an in vitro research study proposal on N-acetyl-glucosamine for PD: https://www.scholars.northwestern.edu/en/projects/development-of-glcnac-as-disease-modifying-treatment-for-parkinso-2
Updates
[2021-1-8]
Very nice review published in October 2020 -
Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?
https://ard.bmj.com/content/79/10/1261
[2021-02-02]
A recent study found that glucosamine acts as a calorie restriction mimetic in senescent rats via mitohormesis - https://pubmed.ncbi.nlm.nih.gov/33478352/
Comments
Post a Comment